Binding of fractalkine to CX3CR1+CD28− T cells results again in enhanced inflammation with tissue damage after secretion of IFN-γ and TNF-α by the effector cells as well as angiogenesis [74, 79], supporting its pathogenic effects in patients with RA. The gene discussed is CX3CR1; the disease is rheumatoid arthritis.